Help us improve Portfolio Grader.

Help us improve Portfolio Grader.

Blue Chip Growth

Stock Report: () Report Updated: Feb 08, 2016 | Print This Page

Get more stock ratings by Louis Navellier


Rating: Volatility:
Total Grade: Industry:

Stock Analysis

Rating: Monthly View

February March April May June July August September October November December January

Rating: Weekly View

This Week: down no change
Last Week: same no change
Two Weeks Ago: up no change
service keys

© quotemedia

Company Profile

3SBio Inc., a biotechnology company, engages in the research and development, manufacture, and distribution of pharmaceutical products in the People’s Republic of China. Its principal products include EPIAO, an injectable recombinant human erythropoietin to stimulate the production of red blood cells in patients with anemia and to reduce the need for blood transfusions; and TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombocytopenia. The company also offers Intefen, a recombinant interferon alpha-2a product for the treatment of carcinoma and viral infectious diseases; Inleusin, a recombinant human IL-2 product to treat renal cell carcinoma, metastatic melanoma, and thoratic fluid build-up caused by cancer and tuberculosis; and Iron Sucrose Supplement, a prescription drug for treating anemia, as well as for patients with end-stage renal disease. In addition, its product pipeline comprises a high dosage EPIAO; NuLeusin for metastatic melanoma and metastatic renal cell carcinoma; Feraheme, an in-licensed intravenous iron replacement therapeutic agent used to treat iron deficiency anemia in chronic kidney disease patients and in patients requiring hemodialysis; Voclosporin, an in-licensed calcineurin inhibitor for use in the prevention of organ rejection following transplantation and treatment of autoimmune diseases; and Pegsiticase, a pegylated recombinant uricase for the treatment of refractory gout and tumor lysis syndrome. Further, the company’s product portfolio includes NuPIAO, a second-generation EPIAO; a human papilloma virus vaccine for the prevention of cervical cancer; and an anti-TNF monoclonal antibody product candidate for treating rheumatoid arthritis, psoriasis, and other inflammatory diseases. It sells its products directly, as well as through its network of distributors to various healthcare providers, such as hospitals, clinics, and dialysis centers. The company was founded in 1993 and is headquartered in Shenyang, China.

Recent News: